Yuanmai Cell Biotechnology Co., Ltd, a macrophage immunotherapy developer based in Nanjing, reportedly raised “tens of millions” of renminbi in an angel financing round. CDH Investments and Renai Group led the funding, which included contributions from Nanjing Jiangbei New Area Sci-tech Investment Group and Nanjing Laoyan Venture Capital. Proceeds will go towards research and development (R&D) platform construction, R&D pipeline expansion, patent filing, and investigator-initiated trials (ITTs).
Company Focus and Technology Platforms
Founded in 2022, Yuanmai Cell is focused on gastric cancer, liver cancer, and prostate cancer, among others. The company boasts an “integrated and non-integrated” molecular editing and manipulation system, iPSC-derived immune cell differentiation system, ligand-receptor, and other information flow recognition and transmission technology platforms.-Fineline Info & Tech
